Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage a number of intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal demo targets ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyo